Orphazyme Revenue and Competitors

DNK

Location

$263.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Orphazyme's estimated annual revenue is currently $13.2M per year.(i)
  • Orphazyme's estimated revenue per employee is $876,667
  • Orphazyme's total funding is $263.3M.
  • Orphazyme's current valuation is $79.8M. (January 2022)

Employee Data

  • Orphazyme has 15 Employees.(i)
  • Orphazyme grew their employee count by -77% last year.

Orphazyme's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7910M33966%$204.3MN/A
#2
$51.3M33120%N/AN/A
#3
$3.4M1338-1%$85.7MN/A
#4
$13.2M15-77%$263.3MN/A
#5
$34.7M22437%N/AN/A
#6
$4.2M2717%N/AN/A
#7
$10.2M6643%N/AN/A
#8
$12.2M7934%N/AN/A
#9
$11.5M7419%N/AN/A
#10
$1.9M12-20%N/AN/A
Add Company

What Is Orphazyme?

Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases, including sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. Anticipated completion of three potential registration studies by end 2020, with the first potential marketing authorization in 2020.

keywords:N/A

$263.3M

Total Funding

15

Number of Employees

$13.2M

Revenue (est)

-77%

Employee Growth %

$79.8M

Valuation

N/A

Accelerator

Orphazyme News

2022-03-30 - Correction: Proposal for a statutory restructuring plan

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in...

2022-03-30 - Proposal for a statutory restructuring plan

Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage...

2022-03-30 - Updated Financial Calendar for 2022

Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage...

2019-08-28 - Orphazyme Partnership to Run Through Extension of Phase 3 ...

Orphazyme announced that it and Worldwide Clinical Trials will continue their collaboration through the long-term extension of a Phase 3 study ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M15-37%N/A
#2
$1.2M15N/AN/A
#3
$1.4M15N/AN/A
#4
$2M15N/AN/A
#5
$2.3M15N/AN/A